Urinary Biomarkers: Is the Era of Exclusive Follow-Up Cystoscopy Coming to an End? A Mini-Review of Emerging Molecular Diagnostics and Risk-Stratified Surveillance
Archives of Cancer Science and Therapy · 08.04.2026 · 10 (1) · 011-015
DOI: 10.29328/journal.acst.1001050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Cancer Science and Therapy, online erschienen am 08.04.2026. Verfasst von Elafari Mohammed Amine und 6 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
Bladder cancer is among the most costly malignancies to treat, primarily due to the high rate of recurrence for Non-Muscle-Invasive Bladder Cancer (NMIBC) and the subsequent necessity for lifelong cystoscopic surveillance. Although cystoscopy is widely regarded as the gold standard, it is an invasive procedure that can be costly and is associated with patient discomfort and anxiety. In recent years, a novel generation of urinary biomarkers (comprising genomic, epigenomic, and proteomic assays) has emerged, exhibiting diagnostic capabilities that increasingly challenge the prevailing role of cystoscopy in surveillance protocols. This mini-review examines the landscape of FDA-approved and emerging urinary biomarkers, compares their diagnostic accuracy, evaluates the first randomized controlled trials supporting biomarker-guided surveillance, and proposes a risk-stratified algorithm for the future integration of urinary biomarkers into clinical practice.
Zitieren
APA
Amine, E. M., Mamad, A., Amine, B. M., Amine, S., Tariq, K., Abdelatif, K., & Khalid, E. (2026). Urinary Biomarkers: Is the Era of Exclusive Follow-Up Cystoscopy Coming to an End? A Mini-Review of Emerging Molecular Diagnostics and Risk-Stratified Surveillance. Archives of Cancer Science and Therapy, 10(1), 011-015. https://doi.org/10.29328/journal.acst.1001050
Vancouver
Amine EM, Mamad A, Amine BM, Amine S, Tariq K, Abdelatif K, et al. Urinary Biomarkers: Is the Era of Exclusive Follow-Up Cystoscopy Coming to an End? A Mini-Review of Emerging Molecular Diagnostics and Risk-Stratified Surveillance. Archives of Cancer Science and Therapy. 2026;10(1):011-015. doi:10.29328/journal.acst.1001050
BibTeX
@article{Amine2026,
author = {Amine, Elafari Mohammed and Mamad, Ayoub and Amine, Bibat Mohammed and Amine, Slaoui and Tariq, Karmouni and Abdelatif, Koutani and Khalid, Elkhader},
title = {Urinary Biomarkers: Is the Era of Exclusive Follow-Up Cystoscopy Coming to an End? A Mini-Review of Emerging Molecular Diagnostics and Risk-Stratified Surveillance},
journal = {Archives of Cancer Science and Therapy},
year = {2026},
volume = {10},
number = {1},
pages = {011--015},
doi = {10.29328/journal.acst.1001050}
}
EUVIMED